Combes Alain, Auzinger Georg, Camporota Luigi, Capellier Gilles, Consales Guglielmo, Couto Antonio Gomis, Dabrowski Wojciech, Davies Roger, Demirkiran Oktay, Gómez Carolina Ferrer, Franz Jutta, Hilty Matthias Peter, Pestaña David, Rovina Nikoletta, Tully Redmond, Turani Franco, Kurz Joerg, Harenski Kai
Institute of Cardiometabolism and Nutrition, INSERM Unité Mixte de Recherche (UMRS) 1166, Sorbonne Université, 47, Boulevard de l'Hôpital, 75013, Paris, France.
Service de Médecine Intensive-Réanimation, Sorbonne Université, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013, Paris, France.
Ann Intensive Care. 2024 Aug 22;14(1):132. doi: 10.1186/s13613-024-01353-8.
By controlling hypercapnia, respiratory acidosis, and associated consequences, extracorporeal CO removal (ECCOR) has the potential to facilitate ultra-protective lung ventilation (UPLV) strategies and to decrease injury from mechanical ventilation. We convened a meeting of European intensivists and nephrologists and used a modified Delphi process to provide updated insights into the role of ECCOR in acute respiratory distress syndrome (ARDS) and to identify recommendations for a future randomized controlled trial.
The group agreed that lung protective ventilation and UPLV should have distinct definitions, with UPLV primarily defined by a tidal volume (V) of 4-6 mL/kg predicted body weight with a driving pressure (ΔP) ≤ 14-15 cmHO. Fourteen (93%) participants agreed that ECCOR would be needed in the majority of patients to implement UPLV. Furthermore, 10 participants (majority, 63%) would select patients with PaO:FiO > 100 mmHg (> 13.3 kPa) and 14 (consensus, 88%) would select patients with a ventilatory ratio of > 2.5-3. A minimum CO removal rate of 80 mL/min delivered by continuous renal support machines was suggested (11/14 participants, 79%) for this objective, using a short, double-lumen catheter inserted into the right internal jugular vein as the preferred vascular access. Of the participants, 14/15 (93%, consensus) stated that a new randomized trial of ECCOR is needed in patients with ARDS. A ΔP of ≥ 14-15 cmHO was suggested by 12/14 participants (86%) as the primary inclusion criterion.
ECCOR may facilitate UPLV with lower volume and pressures provided by the ventilator, while controlling respiratory acidosis. Since recent European Society of Intensive Care Medicine guidelines on ARDS recommended against the use of ECCOR for the treatment of ARDS outside of randomized controlled trials, new trials of ECCOR are urgently needed, with a ΔP of ≥ 14-15 cmHO suggested as the primary inclusion criterion.
通过控制高碳酸血症、呼吸性酸中毒及相关后果,体外二氧化碳清除(ECCOR)有潜力促进肺超保护性通气(UPLV)策略的实施,并减少机械通气造成的损伤。我们召集了欧洲重症医学专家和肾病专家会议,并采用改良的德尔菲法,以提供关于ECCOR在急性呼吸窘迫综合征(ARDS)中作用的最新见解,并确定未来随机对照试验的建议。
该小组一致认为,肺保护性通气和UPLV应有不同的定义,UPLV主要定义为潮气量(V)为4-6 mL/kg预测体重,驱动压(ΔP)≤14-15 cmH₂O。14名(93%)参与者一致认为,大多数患者实施UPLV需要ECCOR。此外,10名参与者(多数,63%)会选择动脉血氧分压与吸入氧浓度比值(PaO₂:FiO₂)>100 mmHg(>13.3 kPa)的患者,14名(共识,88%)会选择通气比>2.5-3的患者。为实现这一目标,建议连续肾脏支持机器的最低二氧化碳清除率为80 mL/min(11/14名参与者,79%),首选血管通路是将一根短的双腔导管插入右颈内静脉。14/15名(93%,共识)参与者表示,ARDS患者需要开展一项新的ECCOR随机试验。12/14名参与者(86%)建议将ΔP≥14-15 cmH₂O作为主要纳入标准。
ECCOR可在控制呼吸性酸中毒的同时,通过较低的潮气量和呼吸机提供的压力促进UPLV。由于欧洲重症监护医学学会最近关于ARDS的指南建议,在随机对照试验之外不建议使用ECCOR治疗ARDS,因此迫切需要开展新的ECCOR试验,建议将ΔP≥14-15 cmH₂O作为主要纳入标准。